Patients new to GLP-1 therapy who want a well-documented starting point with proven, consistent results across a broad population.
- Single receptor target (GLP-1)
- Extensive long-term safety data
- Gradual, steady weight loss
- Well-tolerated at lower doses
Patients seeking the most aggressive clinical approach, or those who have plateaued on single-action GLP-1 medications and want a stronger mechanism.
- Dual receptor target (GLP-1 + GIP)
- Potentially greater total weight loss
- Enhanced metabolic response
- Most advanced mechanism available
Intro Protocol
The Intro Protocol is your entry point into the IVUSE system. Tirzepatide is a dual-action GLP-1 + GIP receptor agonist, the most clinically advanced option available. You've been cleared by our medical team. Once you complete your order, your prescription ships directly to your door.
The 2-month program gives you enough time to see your body respond. The 3-month program allows for full dose escalation, which is where patients tend to see the most significant results.
100% of our surveyed patients said this was easier than past weight loss attempts. Zero said it was harder.
- Licensed physician consultation and prescription
- Tirzepatide medication for the full program duration
- Zofran (ondansetron) for nausea support during adjustment
- Syringes, alcohol swabs, and all injection supplies
- Ongoing medical support and dosage adjustments
- Free priority shipping (3-5 business days)
- Dosing guide and injection instructions
Subcutaneous injection. Stomach, thigh, or upper arm. Once per week, any time of day. Rotate your injection site.
Your physician will start you at a conservative dose and escalate based on your response. The 3-month program allows for the full escalation protocol.
Nausea, diarrhea, and decreased appetite are common during the first two to four weeks. This is your body adjusting. It passes.
Most patients report mild nausea in weeks one and two that resolves with continued use. Serious side effects are rare and monitored by your prescribing provider.
Tirzepatide targets both GLP-1 and GIP receptors, making it a dual-action medication. Clinical data suggests it may produce greater weight loss compared to single-action GLP-1 medications alone.
It is the most advanced option currently available for medical weight management.
Duration: 2 months
Product: Tier 5 Refill
Product: Tier 3 Refill
Product: Tier 3 Refill
Product: Tier 4 Refill
Product: Tier 2 Refill
Product: Tier 2 Refill
